Evidence map›Paper›PMID 30846298›Full record

ArticleEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology2019

Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.

Koji Matsuo, Muneaki Shimada, Keiichiro Nakamura, Yuji Takei, Kimio Ushijima, Toshiyuki Sumi, Tatsuru Ohara, Hideaki Yahata, Mikio Mikami, Toru Sugiyama

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06197126 (A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06197126 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy

TypeobservationalSponsorFujian Cancer HospitalRan2024 to 2028Enrolled200ConditionsCervical Cancer, Radiotherapy, Prognostic Model, MRIArmsTreatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 2 countries.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu.
Muneaki ShimadaDepartment of Obstetrics and Gynecology, Tottori University, Tottori, Japan. Electronic address: muneaki.shimada.b7@tohoku.ac.jp.
Keiichiro NakamuraDepartment of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yuji TakeiDepartment of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan.
Kimio UshijimaDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan.
Toshiyuki SumiDepartment of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tatsuru OharaDepartment of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan.
Hideaki YahataDepartment of Obstetrics and Gynecology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Mikio MikamiDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.
Toru SugiyamaDepartment of Obstetrics and Gynecology, Iwate Medical University, Iwate, Japan.
Iwate Medical University · JPJichi Medical University · JPKurume University · JPKyushu University · JPOkayama University · JPOsaka City University · JPSt. Marianna University School of Medicine · JPTokai University · JPTottori University · JPUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveTo examine predictors of pathological parametrial invasion in clinical stage IIB cervical cancer, and to examine prognostic factors in pathological stage IIB disease.

methodsThis study is an ancillary analysis of a nation-wide retrospective cohort examining 6,003 clinical stage IB-IIB cervical cancers. Women with clinical stage IIB disease who underwent primary radical hysterectomy with lymphadenectomy were examined (n = 714). Multivariate analysis was performed to identify independent clinico-pathological factors for pathological parametrial invasion and to identify independent prognostic factors in pathological stage IIB disease.

resultsParametrial invasion was identified on the surgical specimen in 400 cases (56.0%, 95% confidence interval 52.4-59.7). On multivariate analysis, deep stromal invasion (DSI, adjusted-OR 3.922), multiple pelvic nodal metastases (adjusted-OR 3.266), lympho-vascular space invasion (adjusted-OR 2.333), and uterine corpus invasion (adjusted-OR 1.656) remained independent tumor factors for pathological parametrial invasion. In classification-tree models, tumors with DSI and multiple pelvic nodal metastases had the highest incidence of pathological parametrial invasion (75.0-87.7%); contrary, tumors without DSI had the lowest incidence (21.9%). Among patients with pathological stage IIB disease, the absolute difference in 5-year disease-free survival rates was 57.2%, ranging between 80.9% in those with squamous histology with none/single pelvic nodal metastasis and 23.7% in those with non-squamous histology with multiple pelvic nodal metastases.

conclusionIn clinical stage IIB cervical cancer, accuracy for pathological parametrial invasion is low-modest. With absence of DSI, only one in five clinical stage IIB diseases has pathological stage IIB disease. Survival of pathological stage IIB varies widely and is largely dependent on nodal factors.

Indexed as

AdenocarcinomaAdultAgedCohort StudiesDisease-Free SurvivalFemaleHumansHysterectomyJapanKaplan-Meier EstimateLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoplasm InvasivenessNeoplasm StagingPredictive Value of TestsCervical cancerParametrial invasionRadical hysterectomyStage IIBSurgical-pathological factor

Identifiers

PMID30846298
PMCPMC7523386
OpenAlexW2915131415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.